Immuron CEO, Steven Lydeamore to present at Emerging Growth Conference Melbourne, Australia

Immuron CEO, Steven Lydeamore to present at

Emerging Growth Conference

Melbourne, Australia, January 14, 2026: Immuron

Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting virtually at the

Emerging Growth Conference on Thursday 22nd January 2026 (2:40pm - 2:50pm U.S. Eastern Time).

Please register to ensure you are able to attend this conference and

receive any updates that are released.

If attendees are not able to join the event live

on the day of the conference, an archived webcast will also be made available at https://emerginggrowth.com/profile/IMRN/.

A link will be released after the event.

This release has been authorised by the directors

Chief Executive Officer

Immuron Limited (ASX:

IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal

antibodies for the treatment of infectious diseases.

orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting travelers' diarrhea, a

digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce. Travelan is a highly

purified tabletized preparation of hyper immune bovine antibodies and other factors, which when taken with meals bind to diarrhea-causing

bacteria and prevent colonization and the pathology associated with travelers' diarrhea. In Australia, Travelan is a listed

medicine on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Travelers' Diarrhea,

reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan is a licensed natural health product

(NPN 80046016) and is indicated to reduce the risk of Travelers' Diarrhea. In the U.S., Travelan is sold as a dietary supplement

for digestive tract protection.

TD is generally defined

as the passage of 3 unformed stools per 24 hours plus at least one additional symptom (such as nausea, vomiting, abdominal cramps,

fever, blood/mucus in the stools, or fecal urgency) that develop while abroad or within 10 days of returning from any resource-limited

destinations (Leung et al., 2006). Diarrhea continues to be the most

frequent health problem among travelers to destinations in lower- and middle-income regions (Steffen,

2017). Deployed US military personnel, essentially representing a long-term traveller population, are particularly affected given

their population dynamics and the context in which they seek care and treatment (Connor

et al., 2012). Diarrhea is the leading infectious disease threat to the overall health and preparedness of deployed US armed forces,

with diarrheagenic E. coli, Campylobacter spp., and Shigella spp. among the most commonly reported etiologies (Riddle

Immuron Platform Technology

Immuron's proprietary

technology is based on polyclonal immunoglobulins (IgG) derived from engineered hyper-immune bovine colostrum. Immuron has the capability

of producing highly specific immunoglobulins to any enteric pathogen and our products are orally active. Bovine IgG can withstand the

acidic environment of the stomach and is resistant to proteolysis by the digestive enzymes found in the Gastrointestinal (GI) tract. Bovine

IgG also possesses this unique ability to remain active in the human GI tract delivering its full benefits directly to the bacteria found

there. The underlying nature of Immuron's platform technology enables the development of medicines across a large range of infectious

diseases. The platform can be used to block viruses or bacteria at mucosal surfaces such as the Gastrointestinal tract and neutralize

the toxins they produce.

IMM-124E (Travelan )

IMM-124E was developed

using Immuron's platform technology. IMM-124E is produced from the colostrum of birthing cattle that have been immunised during

pregnancy with a vaccine containing the outer antigens of multiple human derived ETEC. A total of 13 ETEC strains are used in the vaccine

to produce high levels of antibodies against selected surface antigens from the most common strains of ETEC. (Otto

The resultant hyperimmune

colostrum IMM-124E from ETEC vaccinated cows contains significant levels of polyclonal antibodies specific for ETEC antigens LPS, CFA-I

and Flagellin (Sears et al., 2017).

The antibodies produced

in IMM-124E have been found to have a stronger binding and neutralizing activity (than the antibodies of unvaccinated cattle) against

a wide range of LPS antigens including both the variable O-polysaccharide region and the preserved oligosaccharide core R'

region of LPS from the 13 serotypes used in the ETEC vaccine.

IMM-124E is manufactured

into a tablet form referred to as Travelan .

Immuron is developing IMM-529 as an adjunctive

therapy in combination with standard of care antibiotics for the prevention and/or treatment of recurrent Clostridioides difficile infection

(CDI). IMM-529 antibodies targeting Clostridioides difficile (C. diff) may help to clear CDI infection and promote a quicker re-establishment

of normal gut flora, providing an attractive oral preventative for recurrent CDI.

Immuron is collaborating with Dr. Dena Lyras

and her team at Monash University, Australia to develop vaccines to produce bovine colostrum-derived antibodies. Dairy cows were immunised

to generate hyperimmune bovine colostrum (HBC) that contains antibodies targeting three essential C. diff virulence components. IMM-529

targets Toxin B (TcB), the spores and the surface layer proteins of the vegetative cells.

This unique 3-target approach has yielded

promising results in pre-clinical infection and relapse models, including (1) Prevention of primary disease (80% P =0.0052); (2) Protection

of disease recurrence (67%, P <0.01) and (3) Treatment of primary disease (78.6%, P<0.0001; TcB HBC). Importantly IMM-529 antibodies

cross-react with whole cell lysates of many different human strains of C. diff including hypervirulent strains.

To our knowledge, IMM-529 is, to date, the

only investigational drug that has shown therapeutic potential in all three phases of the disease (Hutton

Immuron has an exclusive distribution agreement

with Calmino goup AB for the territories of Australia and New Zealand for ProIBS . ProIBS - to help patients treat IBS symptoms

ProIBS is a certified medical device for the treatment of IBS symptoms such as abdominal pain, bloating and unsettled bowel movements

(diarrhoea and/or constipation). ProIBS contains AVH200 , derived from the plant Aloe barbadensis. Mill. AVH200 has gel

forming components which support the intestinal mucosal barrier. As IBS is known to affect individuals for a long period of time, it is

essential to have a treatment appropriate for long-term use -as ProIBS is. The product is safe, and no interactions with other

medications are known. Science-driven innovative Calmino group AB, the developer of ProIBS , conducted a usability study among 1,003

users. PROIBS was helpful for 94% of them. 91% of the users experienced an improvement in daily life and 98% would recommend PROIBS

to someone else. To learn more please check: www.proibs.eu.

Irritable bowel syndrome (IBS) is a common

condition where you experience symptoms related to your digestive system. This is sometimes linked to certain foods, lifestyle habits

and stress levels or mood. IBS affects around 3 out of every 10 people. Females are more likely than males to be affected. Some key symptoms

of IBS include: abdominal pain or discomfort; stomach bloating and wind; chronic diarrhoea or constipation, or alternating between the

two.(healthdirect.gov.au) According to available data, the

IBS treatment market in Australia is estimated to be a part of the broader "Digestives & Intestinal Remedies" market, generating

a revenue of around AU$221.14 million in 2025, with a projected annual growth rate of 3.28%.(Statista)

Connor P, Porter CK,

Swierczewski B and Riddle MS. Diarrhea during military deployment: current concepts and future directions. Curr Opin Infect Dis. 25(5):

Hutton, M.L., Cunningham,

B.A., Mackin, K.E. et al. Bovine antibodies targeting primary and recurrent Clostridium difficile disease are a potent antibiotic alternative.

Sci Rep 7, 3665 (2017). https://doi.org/10.1038/s41598-017-03982-5

Leung AK, Robson WL,

Davies HD. Travelers' diarrhea. Adv Ther. Jul-Aug; 23(4): 519-27; 2006

Otto W, Najnigier B,

Stelmasiak T and Robins-Browne RM. Randomized control trials using a tablet formulation of hyperimmune bovine colostrum to prevent diarrhea

caused by enterotoxigenic Escherichia coli in volunteers Scandinavian Journal of Gastroenterology 46: 862- 868; 2011.

JW, Putnam SD, and Tribble DR. Incidence, etiology, and impact of diarrhea among long-term travelers' (US military and similar populations):

A systematic review. American Journal of Tropical Medicine and Hygiene. 74(5): 891-900; 2006.

Sears KT, Tennant SM,

Reymann MK, Simon R, Konstantopolos N, Blackwelder WC, Barry EM and Pasetti MF. Bioactive Immune Components of Anti-Diarrheagenic Enterotoxigenic